Trial Search Results

An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed

This large, non-randomized observational study is being conducted to provide data about the impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of non-small cell lung cancer (NSCLC) in a routine medical care setting.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eli Lilly and Company


  • Drug: Pemetrexed




Inclusion Criteria:

   - Non-small cell lung cancer (NSCLC) (any histologic type)

   - Stage IIIB or IV disease

   - Should have had 1 line of chemotherapy for Metastatic disease

   - Adequate hematologic, hepatic and renal function

   - Measurable or evaluable disease

Exclusion Criteria:

   - Pregnant or lactating females

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting